NovaBay Pharmaceuticals, Inc. (NBY)
NYSEAMERICAN: NBY · Real-Time Price · USD
5.30
+2.35 (79.66%)
At close: Dec 19, 2025, 4:00 PM EST
5.44
+0.14 (2.64%)
After-hours: Dec 19, 2025, 8:00 PM EST
NovaBay Pharmaceuticals Revenue
NovaBay Pharmaceuticals had revenue of $521.00K in the quarter ending September 30, 2025. In the year 2024, NovaBay Pharmaceuticals had annual revenue of $9.78M, down -6.45%.
Revenue (ttm)
$9.78M
Revenue Growth
-6.45%
P/S Ratio
3.58
Revenue / Employee
$735,857
Employees
14
Market Cap
667.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.78M | -674.00K | -6.45% |
| Dec 31, 2023 | 10.46M | -3.95M | -27.42% |
| Dec 31, 2022 | 14.40M | 4.20M | 41.16% |
| Dec 31, 2021 | 10.20M | 270.00K | 2.72% |
| Dec 31, 2020 | 9.93M | 3.34M | 50.54% |
| Dec 31, 2019 | 6.60M | -5.91M | -47.24% |
| Dec 31, 2018 | 12.51M | -5.72M | -31.39% |
| Dec 31, 2017 | 18.23M | 6.33M | 53.23% |
| Dec 31, 2016 | 11.90M | 7.52M | 171.56% |
| Dec 31, 2015 | 4.38M | 3.33M | 315.65% |
| Dec 31, 2014 | 1.05M | -2.42M | -69.69% |
| Dec 31, 2013 | 3.48M | -3.47M | -49.95% |
| Dec 31, 2012 | 6.95M | -4.07M | -36.95% |
| Dec 31, 2011 | 11.02M | 1.27M | 12.97% |
| Dec 31, 2010 | 9.75M | -5.93M | -37.81% |
| Dec 31, 2009 | 15.68M | 8.96M | 133.32% |
| Dec 31, 2008 | 6.72M | 809.00K | 13.68% |
| Dec 31, 2007 | 5.91M | 1.43M | 31.96% |
| Jun 30, 2007 | 4.48M | 1.47M | 48.57% |
| Mar 31, 2007 | 3.02M | 1.48M | 96.74% |
| Dec 31, 2006 | 1.53M | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NBY News
- 2 months ago - NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards - GlobeNewsWire
- 3 months ago - NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting - GlobeNewsWire
- 4 months ago - NovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share - GlobeNewsWire
- 4 months ago - NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar - GlobeNewsWire
- 10 months ago - NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders - Business Wire
- 11 months ago - NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal - Business Wire
- 1 year ago - NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders - Business Wire
- 1 year ago - NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting - Business Wire